{"id":21491,"date":"2025-02-04T07:00:10","date_gmt":"2025-02-04T08:00:10","guid":{"rendered":"https:\/\/medexperts.pro\/?p=21491"},"modified":"2025-02-04T08:26:12","modified_gmt":"2025-02-04T08:26:12","slug":"how-an-activist-group-helped-torpedo-mdma-therapy","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=21491","title":{"rendered":"How an Activist Group Helped Torpedo MDMA Therapy"},"content":{"rendered":"
<\/div>\n

The fallout from the F.D.A.\u2019s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.<\/p>\n

\n
\n
\n

After more than three decades of planning and a $250 million investment, Lykos Therapeutics\u2019 application for the first psychedelic drug to reach federal regulators was expected to be a shoo-in.<\/p>\n

Lykos<\/a>, the corporate arm of a nonprofit dedicated to winning mainstream acceptance of psychedelics, had submitted data to the Food and Drug Administration showing that its groundbreaking treatment for post-traumatic stress disorder \u2014 MDMA plus talk therapy \u2014 was significantly more effective<\/a> than existing treatments.<\/p>\n

At a pivotal public hearing<\/a> last summer, two dozen scientists, doctors and trauma survivors told an F.D.A. advisory panel how MDMA-assisted therapy had brought marked relief from a mental health condition associated with high rates of suicide<\/a>, especially among veterans.<\/p>\n

Then came skeptics with disturbing accusations: that Lykos was \u201ca therapy cult,\u201d<\/a> that practitioners in its clinical trials had engaged in widespread abuse of participants and that the company had concealed a litany of adverse events.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

\u201cThe most significant harms in Lykos\u2019s clinical trials were not caused by MDMA, but by the people who were entrusted to supervise its administration,\u201d Ne\u015fe Devenot, one of the speakers opposed to Lykos\u2019s treatment and a writing instructor at Johns Hopkins University, told the committee.<\/p>\n

Dr. Devenot and six others presented themselves as experts in the field of psychedelics, but none had expertise in medicine or therapy. Nor had the speakers disclosed their connection to Psymposia<\/a>, a leftist advocacy group whose members oppose the commercialization of psychedelics and had been campaigning against Lykos and its nonprofit parent, the Multidisciplinary Association for Psychedelic Studies<\/a>, or MAPS.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The fallout from the F.D.A.\u2019s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.After more than three decades of planning and a $250 million investment, Lykos Therapeutics\u2019 application for the first psychedelic drug to reach federal regulators was expected to be a shoo-in.Lykos, the corporate arm of a nonprofit dedicated to winning mainstream acceptance of psychedelics, had submitted data to the Food and Drug Administration showing that its groundbreaking treatment for post-traumatic stress disorder \u2014 MDMA plus talk therapy \u2014 was significantly more effective than existing treatments.At a pivotal public hearing last summer, two dozen scientists, doctors and trauma survivors told an F.D.A. advisory panel how MDMA-assisted therapy had brought marked relief from a mental health condition associated with high rates of suicide, especially among veterans.Then came skeptics with disturbing accusations: that Lykos was \u201ca therapy cult,\u201d that practitioners in its clinical trials had engaged in widespread abuse of participants and that the company had concealed a litany of adverse events.\u201cThe most significant harms in Lykos\u2019s clinical trials were not caused by MDMA, but by the people who were entrusted to supervise its administration,\u201d Ne\u015fe Devenot, one of the speakers opposed to Lykos\u2019s treatment and a writing instructor at Johns Hopkins University, told the committee.Dr. Devenot and six others presented themselves as experts in the field of psychedelics, but none had expertise in medicine or therapy. Nor had the speakers disclosed their connection to Psymposia, a leftist advocacy group whose members oppose the commercialization of psychedelics and had been campaigning against Lykos and its nonprofit parent, the Multidisciplinary Association for Psychedelic Studies, or MAPS.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":21493,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-21491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21491"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21491\/revisions"}],"predecessor-version":[{"id":21494,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21491\/revisions\/21494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/21493"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}